Royce & Associates Invests in Tandem Diabetes Care

Institutional investor takes $6.2 million stake in medical device company

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Royce & Associates LP, an institutional investor, has acquired a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), purchasing 510,000 shares of the medical device company's stock valued at approximately $6.2 million. This represents around 0.75% ownership of Tandem Diabetes Care.

Why it matters

Tandem Diabetes Care is a leading manufacturer of insulin delivery systems and devices for people with insulin-dependent diabetes. The investment by Royce & Associates, a prominent institutional investor, signals confidence in the company's growth potential and innovative product portfolio.

The details

According to a recent 13F filing with the Securities and Exchange Commission, Royce & Associates acquired the new position in Tandem Diabetes Care during the third quarter. The 510,000 shares represent approximately 0.75% of the company's outstanding stock.

  • Royce & Associates acquired the new position in Tandem Diabetes Care during the third quarter.

The players

Royce & Associates LP

An institutional investor and asset management firm.

Tandem Diabetes Care, Inc.

A medical device company focused on the design, development, and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes.

Got photos? Submit your photos here. ›

The takeaway

Royce & Associates' investment in Tandem Diabetes Care underscores the medical device company's strong market position and potential for future growth in the insulin delivery systems industry.